No Data
No Data
Northeast Pharmaceutical Group (000597.SZ): The product pipeline of Dingcheng Peptide Source is in the preclinical research and clinical declaration stage. The company has no substantial income at this stage.
On August 8th, Gelunhui reported that Northeast Pharmaceutical Group (000597.SZ) announced a stock price anomaly notice and signed an Equity Acquisition Framework Agreement with Mr. Zhang Rong. The company intends to acquire 70% of the equity of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. (referred to as 'Dingcheng Peptide Source') with this agreement, which is only a framework agreement for equity acquisition. The specific matters concerning equity acquisition still need to be finalized based on evaluation results, and the transaction arrangement is subject to the formal equity transfer agreement signed by all parties to the transaction. There are still uncertainties in this equity acquisition. As of now, Dingcheng Peptide Source's product pipeline is in the pre-clinical research and clinical declaration stages during this stage.
Northeast Pharmaceutical Group (000597.SZ): Currently, the outlook for vitamin C products is not as pessimistic as before.
On August 8th, Gelonhui reported that Northeast Pharmaceutical Group (000597.SZ) stated during an investor relations event that they are not as pessimistic about vitamin C products as before. They have shifted their focus from supply-demand relations to the quality and excellence of their products.
Northeast Pharmaceutical Group (000597.SZ): The company's PCT patent application has progressed smoothly.
On August 8, Guolong News reported that Northeast Pharmaceutical Group (Stock code: 000597.SZ) stated at an investor relations event that it is not very difficult for insiders to obtain patents, but we place more emphasis on the "FTO" of the product to ensure that the operation does not infringe on others' patents. At present, the company's PCT patent applications are progressing smoothly, and third-party institutions have confirmed the patentability and non-infringement of relevant product patents.
Northeast Pharmaceutical Group (000597.SZ) has acquired 70% equity of Dingcheng Peptide Source, obtaining the specific core technology in the field of cell therapy.
On August 8th, Gelunhui reported that northeast pharmaceutical group (000597.SZ) said at the investor relations event that through the acquisition of Dingcheng Peptide Source's 70% equity, the company has acquired the specificity core technology of the cell therapy field. If they were to establish a team and achieve technical capabilities from scratch, it would take at least an additional 3-5 years.
Investors Continue Waiting On Sidelines For Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
Northeast Pharmaceutical Group (000597.SZ) intends to acquire 70% equity of Dingcheng Peptide Source.
On August 5th, Gelunhui reported that Northeast Pharmaceutical Group (000597.SZ) announced that the company had signed a "Equity Acquisition Framework Agreement" with Mr. Zhang Rong, intending to acquire 70% of the equity of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. (hereinafter referred to as "Dingcheng Peptide Source"). The announcement showed that Dingcheng Peptide Source has formed a complete technical platform and product transformation system for TCR-T and CAR-T cell therapy products, targeting pancreatic cancer, colorectal cancer, gastric cancer, liver cancer and glioma. Developed TCR-T, TCR protein drugs targeted at KRAS mutations, EGFRvIII, AFP, and Claudin18.2 and other targets.
No Data